Clinical Trial

Active Surveillance for Low Risk Prostate Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2021 (before its estimated October 2024 completion). Its status may not reflect the trial's current state.
Summary
An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-10-28; most recent amendment 2021-07-21.
Trial Details
NCT Number NCT04146077
Lead Sponsor I.M. Sechenov First Moscow State Medical University
Collaborators: Moscow Regional Research and Clinical Institute (MONIKI), Pirogov Russian National Research Medical University
Conditions Prostate Cancer, Prostate Adenocarcinoma
Enrollment 100 participants
Start Date 2019-10-01
Primary Completion 2024-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2021-07-22